(R)-1-(2-methoxypyridin-3-yl)ethan-1-ol | 1841092-23-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (R)-1-(2-methoxypyridin-3-yl)ethan-1-ol
• 英文别名: (1R)-1-(2-methoxy-3-pyridyl)ethanol；(1r)-1-(2-Methoxypyridin-3-yl)ethan-1-ol；(1R)-1-(2-methoxypyridin-3-yl)ethanol
• CAS: 1841092-23-6
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: VLIFVHCCBIVTPB-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-1-(2-methoxypyridin-3-yl)ethan-1-ol 在 甲醇 、 三乙基硅烷 、 偶氮二甲酸二异丙酯 、 palladium 10% on activated carbon 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 生成 1-[(1S)-1-(2-methoxy-3-pyridyl)ethyl]pyrazol-4-amine
  参考文献：
  名称：

  [EN] SMALL MOLECULE MODULATORS OF IL-17
  [FR] MODULATEURS À PETITES MOLÉCULES D'IL-17

  摘要：

  The present invention relates to a compound according to formula (I), and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

  公开号：

  WO2023111181A1
• 作为产物：
  描述：

  [(1R)-1-(2-methoxy-3-pyridyl)ethyl] acetate 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 以93 %的产率得到(R)-1-(2-methoxypyridin-3-yl)ethan-1-ol
  参考文献：
  名称：

  [EN] SMALL MOLECULE MODULATORS OF IL-17
  [FR] MODULATEURS À PETITES MOLÉCULES D'IL-17

  摘要：

  The present invention relates to a compound according to formula (I), and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

  公开号：

  WO2023111181A1

文献信息

• [EN] TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF<br/>[FR] PYRIDYLSULFONAMIDES DE CARBAMATE DE TRIAZOLE UTILISÉES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LPA ET LEURS UTILISATIONS
  申请人：GILEAD SCIENCES INC

  公开号：WO2021097039A1

  公开（公告）日：2021-05-20

  The present disclosure relates generally to compounds of Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).

  本公开涉及通常与结合到溶酶磷脂酸受体1（LPAR1）并作为LPAR1拮抗剂的化合物的公式（I）有关。本公开进一步涉及利用这些化合物制备药物治疗通过结合LPAR1引起的疾病和/或病况，包括纤维化和肝病，如非酒精性脂肪性肝炎（NASH）。
• TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：Gilead Sciences, Inc.

  公开号：US20210171500A1

  公开（公告）日：2021-06-10

  The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).